INO
$1.68
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.
Recent News
Inovio Pharmaceuticals Inc (INO) Q4 2025 Earnings Call Highlights: Strategic Moves and ...
Inovio Pharmaceuticals Inc (INO) navigates financial hurdles and regulatory uncertainties while advancing its DNA medicine platform and preparing for potential product launches.
Inovio Pharmaceuticals Q4 Earnings Call Highlights
Inovio Pharmaceuticals (NASDAQ:INO) management used the company’s fourth-quarter and full-year 2025 earnings call to detail progress on its first biologics license application (BLA), ongoing launch preparations, and cost-cutting actions intended to extend cash runway as the FDA reviews INO-3107 for
Inovio: Q4 Earnings Snapshot
PLYMOUTH MEETING, Pa. AP) — Inovio Pharmaceuticals Inc. INO) on Thursday reported fourth-quarter profit of $3.8 million.
Inovio Pharmaceuticals Spotlights INO-3107 BLA Acceptance, FDA Talks Ahead of Oct. 30 PDUFA Date
Inovio Pharmaceuticals (NASDAQ:INO) used an appearance at Oppenheimer’s 36th Annual Life Science Conference to highlight recent regulatory progress for its lead program, INO-3107, and to outline key issues it is working through with the U.S. Food and Drug Administration (FDA) ahead of an October Pre
Is Inovio Pharmaceuticals Stock Going to $0?
This forgotten stock might be too risky even for contrarian investors.